NEW ORAL ANTICOAGULANTS MARKETS
(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers
TABLE OF CONTENTS

1. Introduction 11
   1.1 Scope of this Report 11
   1.2 Methodology 11
   1.3 Executive Summary 12

2. An Overview of Anticoagulants 16
   2.1 Scope of this Chapter 16
   2.1.1 Unmet Medical Needs with Existing Anticoagulants 17
   2.1.2 Pharmacology of Injectable Anticoagulants 18
   2.1.3 Marketed and Registered Drugs for Anticoagulation and Related Disorders 19
   2.2 Oral Anticoagulants 21
   2.2.1 Potential Limitations of New Oral Anticoagulants 23
   2.2.2 Desired Attributes of Anticoagulants 24
   2.2.3 Comparison of New Anticoagulants 24
   2.2.4 Bleed Rates of New Anticoagulants 27

3. Selected Oral Anticoagulants 30
   3.1 Warfarin 30
   3.1.1 Warfarin’s Place in Clinical Therapy 31
   3.1.2 Drug Interaction with Warfarin 31
   3.1.3 Warfarin’s Interactions with Food 32
   3.1.4 Interactions of Warfarin with Dietary Vitamin K 34
   3.2 Dabigatran (Pradaxa) 36
   3.2.1 Use of Dabigatran in Particular Situations 38
   3.2.2 Measuring the Anticoagulant Effect of Dabigatran 38
   3.2.3 Activated Partial Thromboplastin Time (aPTT) 38
   3.2.4 Thrombin Time (TT) and Hemoclot 39
   3.2.5 Ecarin Clotting Time (ECT) 39
   3.2.6 Prothrombin Time (PT) and INR 39
   3.2.7 Measures for Overdose 40
   3.2.8 Management of Bleeding Complications 40
   3.2.9 For Patients Undergoing Surgical Intervention 40
   3.2.10 For Dental Interventions 40
   3.2.11 For Spinal Anesthesia/Epidural Anesthesia/Lumbar Puncture 41
   3.2.12 For Patients with Acute Coronary Syndrome (ACS) 41
   3.2.13 Cardioversion in Dabigatran TreatedPatients 41
   3.2.14 For Patients with Stroke 41
   3.2.15 Dabigatran after Ischemic Stroke 41
   3.2.16 Strengths and Weaknesses of Dabigatran 42
   3.2.16.1 Strengths of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics 42
   3.2.16.2 Weaknesses of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics 43
   3.2.16.3 Strengths of Dabigatran in Laboratory Monitoring 43
   3.2.16.4 Weaknesses of Dabigatran in Laboratory Monitoring 43
   3.2.16.5 Strengths of Dabigatran in Clinical Efficacy 44
   3.2.16.6 Weaknesses of Dabigatran in Clinical Efficacy 44
   3.2.16.7 Strengths of Dabigatran in Controlling Bleeding 44
   3.2.17 Comparison of Dabigatran and Rivaroxaban in Sites of Action 45
   3.3 Rivaroxaban (Xarelto) 45
   3.3.1 Dosage and Administration 46
   3.3.2 Risk of Stroke after Discontinuation in Non-Valvular Atrial Fibrillation 47
   3.3.3 Risk of Bleeding 47
   3.3.4 Bleeding Events in ROCKET AF Trial 48
   3.3.5 Bleeding Events in RECORD Trial 48
5. Coagulation Assays 97
   5.1 Clotting Assays 97
   5.1.1 Chromogenic Methods 97
   5.1.2 Prothrombin Time 97
   5.1.3 Activated Partial Thromboplastin Time 97
   5.1.4 Thrombin Time 97
   5.1.5 Fibrinogen (Clauss Method) 97
   5.1.6 Derived Fibrinogen 97
   5.1.7 Antithrombin 97
   5.1.8 Protein C 97
   5.1.9 Protein S 98
   5.1.10 Lupus Anticoagulants 98
   5.1.11 ProC Global Assay and APC Resistance (APCR) 98
   5.2 Influence of New Anticoagulants on Coagulation Assays 98

6. Disease Conditions Targeted by Anticoagulants 100
   6.1 Cardiovascular Diseases 100
   6.1.1 Stroke 100
   6.1.2 Ischemic Stroke 101
   6.1.3 Hemorragic Stroke 101
   6.1.4 Subarachnoid Hemorragae 102
   6.1.5 Global Incidence and Prevalence of Stroke 102
   6.1.6 Incidence of Stroke in the U.S. 103
   6.1.7 Mortality from Heart Disease and Stroke in Selected OECD Countries 106
   6.1.8 Anticoagulants Used in the Treatment for Stroke 106
   6.1.8.1 Heparin 106
   6.1.8.2 Warfarin 107
   6.1.9 Antiplatelets 107
   6.1.9.1 Aspirin 107
   6.1.9.2 Dipyridamole 107
   6.1.9.3 Clopidogrel 107
   6.1.10 Transient Ischemic Attack (Mini Stroke) 107
   6.1.10.1 Drug Therapy for Mini Stroke 108
   6.1.11 Market for Stroke Medication 108
   6.2 Cardiac Arrhythmia 109
   6.2.1 Tachycardias 109
   6.2.2 Bradycardias 111
   6.2.3 Medications for Arrhythmias 111
   6.2.4 Anticoagulants Used to Treat Arrhythmias 111
   6.2.5 Global Market for Atrial Fibrillation Drugs 111
   6.2.6 Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation 112
   6.2.7 Clinical Data on Direct Thrombin Inhibitors 113
   6.2.7.1 Dabigatran 113
   6.2.7.2 Clinical Data on Oral Factor Xa Inhibitors 116
   6.2.8 Rivaroxaban 116
   6.2.9 Apixaban 117
   6.2.10 Betrixaban 117
   6.2.11 Edoxaban 117
   6.3 Coronary Artery Disease 117
   6.3.1 Global CAD Therapeutics Market 118
   6.3.2 Anticoagulation in Acute Coronary Syndrome 118
   6.3.3 Antiplatelet Therapy 119
   6.3.4 Anticoagulants Therapy 119
   6.4 Heart Attack (Myocardial Infarction) 123
   6.4.1 Global Market for CHF Pharmaceuticals 124
7.2.1 Vitamin K Antagonists 157
7.2.1.1 Global Market for Warfarin 158
7.2.1.2 The Threatened Position of Warfarin in the Anticoagulants Market 159
7.2.1.3 Newer Oral Anticoagulants to Replace Warfarin 160
7.2.1.4 Potential Alternatives to Warfarin 160
7.2.2 Factor Xa Inhibitors 160
7.2.2.1 Global Market for Factor Xa Inhibitors 160
7.2.3 Global Market for Xarelto (Rivaroxaban) 161
7.2.3.1 Xarelto: A Great Promise 162
7.2.3.2 U.S. Market for Xarelto 162
7.2.3.3 U.S. Market Share for Eliquis, Xarelto and Pradaxa 163
7.2.4 Direct Thrombin Inhibitors (DTI) 164
7.2.4.1 Global Market for Direct Thrombin Inhibitors 165
7.2.5 Global Market for Pradaxa (Dabigatran) 166
7.2.5.1 Dawning of the Age of Dabigatran 167
7.2.5.2 Pradaxa: Bringing Potential Sea Change in AF 167
7.2.5.3 Dabigatran’s First Year in the Market 168
7.3 Parenteral Anticoagulants 168
7.3.1 Pharmacology of Parenteral Anticoagulants 169
7.3.2 Adverse Effects of Parenteral Anticoagulants 169
7.3.3 Parenteral Thrombin Inhibitors 170
7.3.3.1 Parenteral Indirect Thrombin Inhibitors 170
7.3.3.2 Market for Unfractionated Heparin (UFH) 171
7.3.3.3 Market for Low Molecular Weight Heparin (LMWH) 172
7.3.3.4 Distribution of LMWH Sales per Indication 173
7.3.4 Global Market for Lovenox 173
7.3.4.1 Lovenox: The Broadest Label 174
7.3.5 Pentasaccharide Anticoagulants 174
7.3.5.1 Fondaparinux (Arixtra) 175
7.3.5.2 Arixtra: A Missed Opportunity 176
7.3.6 Parenteral Direct Thrombin Inhibitors 176
7.3.6.1 Bivalirudin (Angiomax) 176
7.4 Market for Venous Thromboembolic Drugs 177
7.5 Market for Direct Thrombin Inhibitors 178
7.6 Comparisons of Market Opportunities for Anti-Thrombotic Agents 179
7.7 Global Market for Anticoagulants 180
7.7.1 Market Share of Anticoagulants by Type 181
7.8 U.S. Market for Anticoagulants 182
7.9 More Anticoagulants in Pipeline 183
8. Market for Antiplatelets 184
8.1 Overview of this Chapter 184
8.2 The Threatened Market of Plavix 185
8.2.1 Patent Loss of Plavix 186
8.2.2 Patent Loss of Plavix and Competitive Advantages for New Entrants 187
8.3 Market for Effient (Prasugrel) 187
8.3.1 Slow Uptake of Effient 188
8.4 Market for Pletal (Cilostazol) 189
8.5 Market for Activase (Alteplase) 190
8.6 Market for Aggrenox 191
8.7 Market for CardioAspirin 192
8.8 Market for Opalmon 192
8.9 Market for Integrilin (Eptifibatide) 193
8.10 Market for ReoPro (Abciximab) 194
8.11 Market for Brilinta 195
New Oral Anticoagulants Markets

8.12 Market for Diagnostic Assays of Platelet Function 196
8.13 The Anti-Platelet Pipeline 196

9. Deals in Anti-Thrombotic Therapeutics Sector 198
9.1 Sanofi’s Extensive Anti-Thrombotic Partnering Landscape 198
9.2 Daiichi Sankyo’s Licensing Portfolio 199
9.3 Merck & Co. Agreements for Arterial Thrombotic Therapeutics 199
9.4 Deals between Bristol-Myer’s Squibb and Pfizer 200
9.5 Partnership between Ortho-McNeil and Bayer for Xarelto 200

10. Utilization of Anticoagulants and Antiplatelets in the U.S. 201
10.1 Anti-Thrombotic Drugs Used in Asia-Pacific Countries 201
10.2 Antiplatelets Used in Asia-Pacific for Stroke Prevention 201
10.3 Antithrombotic Strategy According to CHADS2 202
10.4 Antithrombotic Strategy for Patients with No Risk Factors (CHADS2=0) 203
10.5 Antithrombotic Strategy for Patients with 1 Risk Factor (CHADS2=1) 204
10.6 Antithrombotic Strategy for Patients with (CHADS2=2) Score 2 205
10.7 Adjustment of INR According to Age 206
10.8 Antithrombotic Treatment for Paroxysmal vs. Persistent AF 207
10.9 Oral Anticoagulation during Tooth Extraction 208
10.10 Oral Anticoagulation during Endoscopy or General Surgery 209
10.11 Oral Anticoagulation during Cardioversion for Persistent AF and Paroxysmal AF 210
10.12 Awareness Levels about New Anticoagulants 211
10.13 Reasons for Prescribing Dabigatran 212

11. Selected Company Profiles 215
11.1 Akers Biosciences, Inc. 215
11.1.1 PIFA Heparin/Platelet Factor 4 Rapid Assay 215
11.2 Anthera Pharmaceuticals, Inc. 215
11.2.1 Varespladib/A-002 216
11.3 ARYx Therapeutics, Inc. 216
11.3.1 Tecarfarin 216
11.3.2 Tecarfarin Development Status 217
11.4 AstraZeneca, PLC 217
11.4.1 Brilinta (Ticagrelor) 218
11.5 Boehringer Ingelheim GmbH 218
11.5.1 Boehringer’s Dedication to Innovation 218
11.5.2 Boehringer’s Therapeutic Breakthrough 219
11.5.3 Registration Study RE-LY 219
11.6 Cipla Limited 220
11.7 Daiichi Sankyo Company Ltd. 221
11.7.1 LIEXIANA 221
11.8 Eisai Co., Ltd. 221
11.8.1 Fragmin 221
11.9 Eli Lilly & Co. 222
11.9.1 Effient (Daiichi Sankyo) 222
11.9.2 General Risk of Bleeding 223
11.9.3 Coronary Artery By-Pass Graft Surgery-Related Bleeding 224
11.9.4 Discontinuation of Effient 224
11.9.5 Thrombotic Thrombocytopenic Purpura 224
11.9.6 Hypersensitivity Including Angiodema 225
11.9.7 Clinical Studies 225
11.10 Genentech, Inc. 227
11.10.1 Activase (Alteplase) 227
11.11 GlaxoSmithKline PLC 227
Figure 6.11: Management of UA/NSTEMI 119
Figure 6.12: Global Market for CHF Pharmaceuticals, 2012-2019 124
Figure 6.13: Global Market for Prosthetic Heart Valves, 2012-2019 126
Figure 6.14: Global Market for Mechanical Heart Valves, 2012-2019 127
Figure 6.15: Global Market for Tissue Heart Valves, 2012-2019 128
Figure 6.16: Recommendations from the Seventh ACCP Consensus Conference 129
Figure 6.17: Algorithm for Antithrombotic Therapy for Prosthetic Heart Valves 130
Figure 6.18: Phases of VT and Conventional Treatments with Anticoagulants 135
Figure 6.19: Estimated Increase of THR and TKR in the U.S., 2005-2030 136
Figure 6.20: Hip Replacement Surgery in OECD Countries, 2009 137
Figure 6.21: Knee Replacement Surgeries in OECD Countries, 2009 138
Figure 6.22: U.S. Hip Replacement Market, 2012-2019 140
Figure 6.23: U.S. Knee Replacement Market, 2012-2019 141
Figure 6.24: Global Shoulder Replacement Market, 2012-2019 142
Figure 6.25: Global Market for Hemodialysis, 2012-2019 148
Figure 6.26: Percent Global Operators of Dialysis Clinics by Country, 2011 149
Figure 6.27: Global Leaders in Dialysis Products 149
Figure 6.28: Global Hemodialysis Products Market by Vendor, 2011 150
Figure 6.29: Global Leaders in Peritoneal Dialysis Products Market, 2011 150
Figure 6.30: Global Market for Cancer Therapeutics, 2012-2019 152
Figure 7.1: Estimated Global Market for Coagulation Testing, 2012-2019 155
Figure 7.2: Anticoagulant Market Segments 156
Figure 7.3: Mechanism of Action of Warfarin 158
Figure 7.4: Global Market for Warfarin, 2011-2016 159
Figure 7.5: Global Market for Factor Xa Inhibitors, 2012-2019 161
Figure 7.6: Global Market for Rivaroxaban, 2012-2019 162
Figure 7.7: U.S. Market for Xarelto, 2012-2019 163
Figure 7.8: Estimated U.S. Market Share of New Anticoagulants in 2019 164
Figure 7.9: Binding Sites of Univalent and Bivalent DTIs 164
Figure 7.10: Global Market for Direct Thrombin Inhibitors, 2012-2019 166
Figure 7.11: Global Market for Pradaxa (Dabigatran), 2012-2019 167
Figure 7.12: Mechanism of Thrombin Inhibition 170
Figure 7.13: Mechanism of Action of Indirect Thrombin Inhibitors 171
Figure 7.14: Global Market for Unfractionated Heparin (UFH), 2012-2019 171
Figure 7.15: Global Market for LMWHs, 2012-2019 172
Figure 7.16: Distribution of LMWH Sales per Indication 173
Figure 7.17: Global Market for Lovenox (Enoxaparin), 2012-2019 174
Figure 7.18: Sales of Arixtra, 2005-2009 175
Figure 7.19: U.S. Sales of Angiomax, 2001-2010 177
Figure 7.20: Global Market for Venous Thromboembolic Drugs, 2012-2019 178
Figure 7.21: Global Market for Direct Thrombin Inhibitors, 2012-2019 179
Figure 7.22: Overall Global Market for Anticoagulants, 2012-2019 181
Figure 7.23: Global Market Share of Anticoagulants by Type, 2011 182
Figure 7.24: U.S. Market for Anticoagulants, 2012-2019 182
Figure 8.1: Global Market for Antiplatelets, 2012-2019 185
Figure 8.2: The Declining Market for Plavix, 2012-2015 186
Figure 8.3: Market for Effient (Prasugrel), 2012-2019 188
Figure 8.4: Market for Pletal, 2012-2019 190
Figure 8.5: Market for Activase (Alteplase), 2012-2019 191
Figure 8.6: Market for Aggrenox, 2012-2019 191
Figure 8.7: Market for CardioAspirin, 2012-2019 192
Figure 8.8: Market for Opalmon (Limaprost), 2012-2019 193
Figure 8.9: Market for Integrilin, 2012-2019 194
Figure 8.10: Market for ReoPro, 2012-2019 195
Figure 8.11: Estimated Market for Diagnostic Assays of Platelet Function, 2013-2018 196
INDEX OF TABLES

Table 2.1: Limitations and Consequences of Vitamin K Antagonists 18
Table 2.2: Pharmacokinetics of Injectable Anticoagulants 18
Table 2.3: Marketed and Registered Drugs for Anticoagulation and Related Disorders 19
Table 2.4: Desired Attributes of Newly Developed Anticoagulants 24
Table 2.5: Comparison of New Anticoagulants 25
Table 3.1: Examples of Drugs that Interact with Warfarin 32
Table 3.2: Vitamin K Content of Selected Vegetables 33
Table 3.3: Weekly Requirements of Vegetables Based on Age and Gender 34
Table 3.4: Vitamin K Content of Commonly Used Oils 34
Table 3.5: Vitamin K Content in the Oil of Fast and Processed Foods 35
Table 3.6: Vitamin K Content in Nutritional Supplements per 8 OZ 35
Table 3.7: Mean Dabigatran Plasma Concentration and the 25th-75th Percentiles 38
Table 3.8: Discontinuation Rules before Surgical Procedures 40
Table 3.9: Strengths and Weaknesses of Dabigatran Compared with Others 43
Table 3.10: Bleeding Events in ROCKET AF Trial 48
Table 3.11: Bleeding Events in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD) 49
Table 3.12: Other Adverse Reactions Reported in RECORD 1-3 Studies 50
Table 3.13: Clinical Outcomes of EINSTEIN PE 51
Table 3.14: Primary Composite Endpoint Results in ROCKET AF Study 51
Table 3.15: Key Efficacy Analysis Results from RECORD Trial 53
Table 3.16: Phase III AF Trials 58
Table 3.17: Drugs in Development for Anticoagulation and Related Disorders 63
Table 3.18: Comparison of Oral Anticoagulants 66
Table 3.19: Pharmacokinetic Parameters after Five Days of 1.5 mg/kg SC Once Daily Doses of Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations 73
Table 3.20: Pharmacokinetic Parameters of Fondaparinux and Other Anticoagulants 74
Table 3.21: Composition of 20,000 Anti-Xa IU/mL Innohep 74
Table 3.22: Comparison of Characteristics of AVE5026, Idrabiotaparinux, Otamixaban and RB006 76
Table 4.1: Comparison of Top Five Antiplatelets 83
Table 4.2: Estimated Yearly Incidence of Bleeding with Antiplatelets 85
Table 4.3: Summary of Evidence for Antiplatelets 86
Table 4.4: Cost of Antiplatelets 86
Table 4.5: Information on Ticagrelor 91
Table 4.6: Product Information on Clopidogrel 93
Table 4.7: CURE Incidence of Bleeding Complications (% Patients) 94
Table 4.8: Incidence of Bleeding Event in COMMIT (% Patients) 95
Table 5.1: Influence of Anticoagulants on Routine Coagulation Assays 99
Table 5.2: Influence of Anticoagulants on Thrombophilia Assays 99
Table 6.1: ACC/AHS Recommendations for Antiplatelet Therapy in Patients with NSTEMI or UA 119
Table 6.2: Dosing of LMWH, Fondaparinux and Bivalirudin in Patients with NSTEMI or UA 120
Table 6.3: ACC/AHA Recommendations for Anticoagulants Therapy in Patients with NSTEMI or UA 120
Table 6.4: Antiplatelet Therapy in Patients with STEMI 121
Table 6.5: Anticoagulants Therapy in Patients with STEMI Who Receive Fibrinolytic Therapy 121
Table 6.6: Anticoagulants Therapy in Patients with STEMI Who Undergo Primary PCI 122
Table 6.7: ACCP Recommendations for Thromboprophylactic Strategy Based on Risk for VTE 122
Table 6.8: Anticoagulants Treatments for VTE 123
Table 6.9: Projections of Crude Cardiovascular Disease Prevalence, 2010-2030 125
Table 6.10: Projected Direct Medical Costs for Cardiovascular Diseases, 2010-2030 125
Table 6.11: Hamilton Score 131
Table 6.12: Modified Wells Score 132
Table 6.13: Low Molecular Weight Heparin or Pentasaccharide Indications for VTE Treatment 133
Table 6.14: Drugs to Prevent Thromboembolism after Hip Fracture 145
Table 6.15: Complete Blood Count Components 147
Table 7.1: Oral Anticoagulants Utilization and Cost per Claim 156
Table 7.2: Oral Anticoagulation Utilization by Age Band, 2011 157
Table 7.3: Users New to Anticoagulation Therapy and Switch Rate, 2011 157
Table 7.4: Alternatives to Warfarin 160
Table 7.5: FDA-Approved Direct Thrombin Inhibitors 165
Table 7.6: FDA-Approved Parenteral Anticoagulants 169
Table 7.7: Pharmacokinetics of Parenteral Anticoagulants 169
Table 7.8: Adverse Effects of Parenteral Anticoagulants 170
Table 7.9: Available Forms of Parenteral Anticoagulants 170
Table 7.10: Characteristics of Available LMWH 173
Table 7.11: Risk Factors for Venous Thromboembolism 177
Table 7.12: Anti-Thrombotic Agents Market, 2012 and 2019 180
Table 7.13: Partial List of Anticoagulants in Development 183
Table 8.1: Comparison of Antiplatelets 184
Table 8.2: History of Prasugrel 189
Table 9.1: Selected Sanofi’s Agreements for Antithrombotics 199
Table 9.2: Selected Daiichi Sankyo’s Agreements for Anti-Thrombotics 199
Table 9.3: Agreements for Integristin 200
Table 9.4: Agreements for Aggrastat 200
Table 9.5: Notable High-Value Deals for Anti-Thrombotics 200
Table 11.1: Cipla’s Anticoagulant and Antithrombotic Products 220
Table 11.2: Dosage and Administration of Fragmin 222
Table 11.3: Patients with Outcome Events in TRITON-TIMI 38 227
Table 11.4: Medication Information for Tinzaparin 231
Table 11.5: Product Pipeline from Portola 232
Table 11.6: Dosage and Administration of Lovenox 233
Table A1.1: Risk Factors for Thromboembolism and Latest Guideline Management Recommendations 235
Table A1.2: Comparison of the Three Studies of New Anticoagulants for Atrial Fibrillation 240
1. **Introduction**

Anticoagulants are sometimes referred to as blood thinners, as they help in preventing blood clots from forming to minimize the risk of heart attack, stroke and blockages in arteries and veins. However, anticoagulants cannot break up the blocks that have already been formed in the arteries and veins. Anticoagulants are prescribed for patients with heart valve implants, atrial fibrillation (irregular heart beat) and cardiomyopathy that increase the risk of developing blood clots. Though they are called blood thinners, in reality, they do not thin the blood but simply decrease the ability of the blood to create harmful blood clots that may potentially block the arteries and veins, ultimately leading to a heart attack or stroke. For more than 50 years and until recently, the only oral anticoagulants were the vitamin K antagonists such as warfarin. Within the past few years, several new oral anticoagulants (NOACs) have entered the market. These products, such as Pradaxa (dabigatran) and Xarelto (rivaroxaban), are commercially available, and Eliquis (apixaban) is expected to be approved in the United States (U.S.) and European Union (E.U.). These and the other new oral anticoagulants in the horizon have several advantages over warfarin. They do not interact with food or other drugs, and thus produce a predictable effect with fixed doses. They need no periodical laboratory monitoring, and thus they are more convenient to administer than warfarin. This TriMark Publications report provides a thorough overview of the new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and the respective areas of market growth with projections.

1.1 **Scope of this Report**

The report provides a thorough overview of anticoagulants, including FDA-approved indications, pharmacokinetic parameters, areas of market growth and unmet medical needs. The near-term and expected changes paved by the introduction of oral anticoagulants and the prophylactic market will be assessed in light of market opportunities and influence of at least two new therapeutic options expected to reach commercialization. The second chapter of this report provides an insight into the structure and mechanism of action of the key oral anticoagulants of interest, dabigatran, rivaroxaban, apixaban and edoxaban, as well as other pipeline agents within this class. Also cataloged are selected parenteral anticoagulants such as unfractionated heparins (UFH); low molecular weight heparins (LMWH); dalteparin (Fragmin); enoxaparin (Lovenox); fondaparinux (Arixtra); and tinzaparin (Innohep). Anticoagulants therapy is necessitated in most of the surgical procedures except the cosmetic surgeries; the third chapter of this report deals with the global and regional markets for surgical applications, such as for orthopedic procedures. The fourth chapter of this report is the largest section and it deals with the market analysis of the various anticoagulants and antiplatelet drugs available in the market. This section also offers an insight into the drugs that are slowly getting phased out of the market and the newer drugs that poised to reshape the market. The fifth chapter of this report gives brief accounts of the profiles of companies that are focused on developing and marketing anticoagulant drugs. The appendix section of this report provides valuable information on the market trends for various pharmaceutical drugs in the global and U.S. level.

1.2 **Methodology**

The authors of this report include a tenured Ph.D.-trained (University of California) professional with extensive experience with the cardiovascular treatment landscape, and, a retired professor of biochemical pharmacology with several years experience in market research. Company-specific information for this report has been obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include the non-governmental organizations (NGOs) and relevant medical societies.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources in which TriMark has high confidence. TriMark cannot guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for the purposes of this report.
Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. TriMark extracts relevant data and analytics from TriMark’s research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.

- Formulating a study outline with the assigned writer, including important items, as follows:
  - Market and product segment grouping, and evaluating their relative significance.
  - Key competitors’ evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
  - Supply chain research and analysis to identify any factors affecting the market.
  - New technology platforms and cutting-edge applications.

- Identifying the key technology and market trends that drive or affect these markets.

- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.

- Completing a confirmatory primary research assessment of the report’s findings with the assistance of expert panel partners from the industry being analyzed.

1.3 Executive Summary

The anticoagulants market is on the threshold of a potential major shift in clinical practice, from a market monopolized by a single, injectable anticoagulant to a highly competitive market dominated by newer oral anticoagulants. There is intense activity in the anticoagulant drug development space as companies are competing with each other to launch novel therapies which offer superior safety, efficacy and convenience to patients and physicians, a medical need which has gone unfulfilled for decades. In 2012, the global market for warfarin stood at about $200 million. Warfarin has been in the anticoagulants market for more than 50 years and with the introduction of new drugs in the recent past, improved options will capture a large share of the market. The cost savings of warfarin, however, as well as continuity for patients doing well with warfarin, will keep warfarin a significant part of the market indefinitely. Yet, due to convenience of use and other factors of other agents, warfarin is expected to lose its ground and give way to other oral anticoagulants in the near future. Present market trends indicate that warfarin may gradually become phased out in 2017 or 2018. Yet, it is a remarkable survival rate for a drug that dominated the anticoagulation sector for more than 50 years.
Two agents, classified as ‘newer oral anticoagulant drugs’ have begun entering the market and are expected to recast antithrombotic therapy by offering effective, less cumbersome alternatives to the standard of care for chronic anticoagulation warfarin. These drugs are Pradaxa (dabigatran), an oral direct thrombin inhibitor; Xarelto (rivaroxaban), an oral factor Xa inhibitor; Eliquis (apixaban), an oral factor Xa inhibitor; and edoxaban, also an oral factor Xa inhibitor. In the U.S. more than [redacted] prescriptions have been filled for Pradaxa 150 mg and more than [redacted] atrial fibrillation patients have been prescribed with Pradaxa 75 mg since its approval in [redacted]. The global market for dabigatran was worth about $[redacted] in [redacted] and this market will have a value of about $[redacted] in [redacted]. In Canada, where the national healthcare system views the convenience of oral anticoagulants therapy as superior to warfarin, uptake has been even more rapid.

The once-daily dosing of Xarelto is a plus. Both Pradaxa and Xarelto are cleared renally. Xarelto also has limited hepatic clearance. For patients with renal impairment, warfarin may remain the best option. Otherwise use of concomitant medications may factor into treatment choice. The half-life of Xarelto is the shorter of the two; for patients (or physicians) concerned about drug reversal, this may or may not be a differentiator.

For the prophylaxis of venous thromboembolism, rivaroxaban represents a broader therapeutic window, less monitoring, and easier dosing than heparin or Arixtra. It also has a decreased risk for thrombocytopenia as compared to Arixtra. Eli Lily’s LY-517717 is slated to enter the market in [redacted] and appears to possess comparable efficacy and possibly superior safety than existing agents.

Rivaroxaban has been in the U.S. market since [redacted]. Globally, rivaroxaban had a market valued at $[redacted] in [redacted] and this figure is predicted to reach $[redacted] in [redacted]. Though some analysts consider apixaban (Eliquis) the future front-runner based on its slightly superior profile, it will need to overcome third-to-market status. Eliquis (apixaban; BMS/PFE) received EMA approval most recently, on [redacted], with FDA approval anticipated by [redacted]. Accordingly, the success of its market launch is yet to be gauged. Edoxaban is from Daiichi Sankyo and the company received marketing approval in [redacted] from the Japanese Ministry of Health, Labor and Welfare. This oral anticoagulant is yet to make its impact in the global market. Edoxaban is a once-daily oral anticoagulant that is currently available only in Japan.

These newer oral anticoagulants are poised to become the standard of care for stroke prevention for atrial fibrillation patients. The directionality and magnitude of the mortality reduction is consistent and approximates a reduced relative risk of 10% per year. These drugs are also expected to seize significant market share from the injectable anticoagulants for prophylaxis of venous thromboembolism in orthopedic surgery. The major shaper yet to be seen is in physician education. Whereas warfarin is managed by specialists adept with the nuances of the agent—at Coumadin clinics—the availability of oral anticoagulants puts anticoagulation into the hands of nonspecialists. It should be noted that although oral anticoagulants are less “finicky” than warfarin, blood thinning inherently requires monitoring and intimate familiarity with the drug interactions and other drug attributes. Oral anticoagulants are far less safe than traditional agents used for cardiovascular disorders, such as ace inhibitors or statins. In the case of these preventative agents, preventative cardiologists, internists, and even community family doctors can be at ease in managing the potential safety, adherence and drug interactions of the agents. In the present case, however, a prescriber physician needs to be fully versed and conducting monitoring to ensure that the extent of anticoagulation is appropriate. Too little, and the patient remains at risk. Too much, and the patient can sustain internal bleeds that can prove fatal. Moreover, both patient and physician must be fully educated on the half-life of the particular, to be taken into account before any surgical or invasive procedure.

Despite the staggering opportunity afforded through long-term, prophylactic acute coronary syndrome (ACS) market, imperfections in this patina are starting to appear. Bleeds are inherent of any anticoagulant therapy. In [redacted], the FDA released the findings of the SENTINEL Study, a postmarketing insurance claims database analysis of dabigatran bleeds and found, rather conclusively, that bleed rate does not exceed that of warfarin.

An important consequence of the nuances of the individual newer oral anticoagulants is that a given physician and institution is likely to choose one oral anticoagulant for use in most patients. This would be a practical, even advisable, step towards increasing safety, efficacy and tolerability with the use of newer oral anticoagulants. Indeed, TriMark experts who have been among the hundreds of investigators remain adopters of Pradaxa or Xarelto and on which they have clinical experience.
Both “camps” are happy with their choice of therapy, but few of TriMark’s opinion leaders report switching between the two available agents, although both are on formulary. Only the savviest prescribers report that they have built comfort and use both extensively in their clinical practice; drug of choice being driven by patient profile. Most, however, maintain a “go to” drug for the vast majority of their scripts, and resort to the other option only when necessary based on patient profile.

Expert opinion is consistent that the commercialized and emerging oral anticoagulants are overall comparable in efficacy. Although each agent may be shown to excel for one patient population or indication—or in a particular clinical trial (given its particular study design and cohort), members of this class are largely viewed as equally acceptable drug options. Treatment of choice will likely be determined by the patient-specific variables, including drug-Dose interactions and preferred route of clearance. Towards this end, it may be expected that patients will be often referred to the care of a cardiologist or anticoagulation clinic.

Injectable anticoagulants have hospital-based critical care applications, mainly for cardiac indications, for which rapid acting, reversible agents are well suited. Drugs such as Lovenox (enoxaparin sodium), Arixtra (fondaparinux sodium), Fragmin (dalteparin sodium) and Angiomax (desirudin) along with unfractionated heparin (UFH) will likely stay put and dominate critical care due to their advantageous pharmacological properties. Unfractionated heparins have been in clinical use for several years but their position is being threatened with the arrival of other new anticoagulants. In its heydays, it enjoyed a market share of more than $[XXX], but in [YYYY] its market was valued only at $[XXX] and this is further expected to decline and reach only $[XXX] in [YYYY]. Same is the case with low molecular weight heparins. The LMWH had a market of about $[XXX] in [YYYY], but it is expected to decline steeply and reach $[XXX] in [YYYY]. Sanofi-Aventis’ Lovenox is also seriously threatened by a generic copycat version. The anticoagulants market is forecast to experience significant growth during the analysis period as premium priced therapies gradually replace the widely used inexpensive generic warfarin, while at the same time attracting new patients previously left untreated with no therapeutic options. Safety, mainly with regard to bleeding, is a key for regulatory, patient and physician acceptance of new therapies, and it is understood that this factor will primarily drive market share for emerging anticoagulant drugs.

In the recent past, several new antiplatelet drugs have been approved to expand the armory of the treating physician. Until a few years ago, clopidogrel (Plavix) dominated the oral antiplatelet market with a 66% share. Clopidogrel lost patent protection in Europe in [YYYY] and in the U.S. it is to lose the patent rights in [YYYY]. This has caused sales of this drug to plummet to less than 25% of former sales highs. Plavix had a market worth of about $[XXX] in [YYYY], and it is predicted that the drug will survive only up to [YYYY] when its market value will be only about $[XXX].

Prasugrel (Effient) is an oral antiplatelet drug that targets platelet aggregations. It was discovered by Daiichi Sankyo and its Japanese research partner Ube Industries Ltd. It is now being marketed by Daiichi Sankyo and Eli Lilly and Company. The global market for prasugrel in [YYYY] was worth about $[XXX] and the favorable market for the drug indicates that it will grow and reach $[XXX] in [YYYY]. Pharmaceutical industry analysts have tipped prasugrel as a potential blockbuster. The other antiplatelet drugs available in the market are pletal, activase, aggreganox, cardioaspirin, opalman, integrillin and ReoPro. Except integrillin and ReoPro, all the other antiplatelet drugs have been witnessing a growing market.